Insider · CIK 0001652799
Daniel E. Ryweck
Files at SILO (Silo Pharma, Inc.). First filing -, latest -.
In brief
Daniel E. Ryweck files SEC Form 4 as CFO at SILO (Silo Pharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Daniel E. Ryweck has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 23, 2025 | SILO Silo Pharma, Inc. | AGrant or award Options (right to buy)derivative | +50,000 | $0.00 | $0 | 55,000 | May 27, 2025 |
Questions about Daniel E. Ryweck
Answered from the filings on this page, as of the latest one.
Is Daniel E. Ryweck buying or selling?
Daniel E. Ryweck has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Daniel E. Ryweck's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel E. Ryweck has 0.
Where does Daniel E. Ryweck file Form 4?
Daniel E. Ryweck has filed Form 4 at SILO (Silo Pharma, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.